ARTICLE | Clinical News
PL-3994: Phase IIa started
May 26, 2008 7:00 AM UTC
Palatin began a double-blind, placebo-controlled, single-ascending dose, U.S. Phase IIa trial to evaluate five dose levels of subcutaneous PL-3994 in about 35 patients with controlled hypertension. ...